Report Forecasts Proteomics Market at $2.68B in 2008
A new study forecasts that the proteomics market will grow to $2.68 billion in 2008, from $1.52 billion in 2003— a less bold projection than that of a report by the same firm in 2001.
The report, by Front Line Strategic Management Consulting, predicts that the proteomics market will grow at a 12 percent overall compound annual growth rate for the next five years. Currently, the report says, protein separation has 51 percent of the market share for proteomics revenues, with the remainder being occupied by protein characterization, content and informatics, and services.
Additionally, Front Line’s analysts see the geographic breakdown of the current market being 45 percent in the US, 40 percent in Europe, and 10 percent in Japan. The report predicts that proteomics will find future applications in agriculture, biodefense, clinical diagnostics, gene therapy, and oncology.
A June 2001 proteomics market forecast by Front Line predicted that the proteomics market would increase from a $561 million market to a $2.8 billion market by 2005.
Another forecast, released by Frost & Sullivan in August 2001, was even more rosy, putting the proteomics market at $5.6 billion by 2006.
The current Front Line report sells for $5,100.
Inpharmatica and Chiron Pen Informatics Alliance
Inpharmatica of London has won a deal to prioritize protein targets for Chiron, using its PharmaCarta chemogenomics informatics platform, the company said last week.
Inpharmatica plans to apply the technology platform, which is used to functionally annotate full-length proteins, to assess the druggability of proteins in genomic datasets from Chiron’s oncology research program.
The agreement is Inpharmatica’s second relationship involving the application of its technology outside its own internal discovery programs and the first involving druggability assessment. In January, the company expanded an existing research collaboration with Serono.
Syracuse Proteomics Symposium Planned
Cornell and other sponsors are convening a symposium on proteomics in Syracuse, NY March 17. Among the speakers slated to present are former Celera proteomics head Scott Patterson, who is the new CSO of Farmal Biomedicines, protein mass spec pioneer Fred McLafferty; and New York Congressman Jim Walsh (R-25th Dist.).
Sidec and Procognia Sign Deal
Sidec of Stockholm, Sweden, has signed a contract with Procognia of the UK, to use its protein imaging technology to locate protein glycosylation sites on proteins that Procognia supplies, Sidec said last week.
The technology, according to Sidec, enables users to make a three-dimensional reconstruction of multiple protein structures in a single analysis.
As Procognia has developed a technology to identify glycosylation patterns of intact proteins, it is looking to use the technology to better characterize those patterns for its protein drug discovery programs, and development, and manufacture of protein-based pharmaceuticals.
Sidec is a spinout of the Karolinska Institute.
Mayo Clinic Cuts Hole in Roof For Mass Spec Magnet
The Keck FT-ICR Mass Spectrometry Laboratory at the Mayo Clinic has cut a hole in its roof to prepare for the arrival of an ultra high-field 12 Tesla-strength magnet from Bruker Daltonics.
The magnet, slated for arrival Feb. 27, will be part of the new FT-ICR protein mass spectrometer, which will be the second highest field mass spectrometer in the world, according to the Mayo Clinic. The Keck lab has nine other smaller mass spectrometers.
Together, Bruker and Keck lab researchers custom-designed the FT-ICR mass spectrometer. The magnet itself was made in Yarnton, UK, by Magnex Scientific.
“This high-end instrumentation allows us to approach mammalian proteomes with confidence,” David Muddiman, director of the Keck lab, said in a statement.
Xerion Gets Rights to Tufts Cancer Targets
Xerion Pharmaceuticals has obtained exclusive rights to protein targets for cancer identified at a Tufts University lab.
The Martinsried, Germany, firm plans to use the targets, which were identified in the lab of Daniel Jay, to create therapeutic antibodies.
Xerion was founded in 1998 by former MorphoSys employees and is based on a technology developed by Jay. The technology, Chromophore-Assisted Laser Inactivation (CALI), is designed to determine how proteins act in situ. by inactivating proteins in living cells and embryos at precise times and locations.